Xconomy

MAY 10, 2019

The market for drugs for rare or “orphan” diseases continues to grow. The field has gotten so competitive that multiple products are on the market for some diseases. Patients with the rare, debilitating transthyretin amyloidosis had no marketed. Soon there could be three.

Pricing 97

Pricing Sales Competition Report 97

Xconomy

JUNE 14, 2019

The US Federal Trade Commission wants yet more information about the buyout, and overseas, the UK Competition and Markets Authority opened a separate investigation. This past week, antitrust regulators once again delayed Roche’s planned $4.8 billion buyout of gene therapy developer Spark Therapeutics (NASDAQ: ONCE ).

News 97

News Competition Acquisition Report 97

Xconomy

MAY 17, 2019

During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. A lawsuit is now claiming that many top generic drug makers routinely conspired to avoid competition. But such tools only work when companies play fair.

Pricing 79

Pricing Competition Tool Marketing 79

socalTECH

DECEMBER 10, 2010

to San Diego. Marketing , Costello and Sons Insurance , Deloitte , The City of. Binary Pulse Technology Marketing (www.binarypulse.com). pushing CEOs and business owners to innovate to outperform the competition. your business on the map with national news coverage and blog buzz for only $999 a. learn more.

SoCalTech 127

SoCalTech Advertising Rustic Canyon Glendale 127

Xconomy

FEBRUARY 21, 2020

The FDA is trying to tame high insulin prices by encouraging price competition. When the change takes effect on March 23, would-be competitors will be able to seek approval for products that are biologically similar to the branded insulin now on the market, the. The FDA has historically regarded insulin as a drug.

Pricing 79

Pricing Competition Product Marketing 79

Xconomy

OCTOBER 2, 2019

A new mobility company, Cerence , is making its public-market debut Wednesday, and its first CEO, Sanjay Dhawan, says he’s been meeting with more than 50 investors in recent weeks to talk up its prospects. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Artificial Inteligence 52

Artificial Inteligence Mobile Competition Activity 52

Xconomy

JULY 26, 2019

He steered Vertex through a crisis when its hepatitis C business was squashed by competition. Vertex surprised Wall Street this week by announcing Leiden’s seven-year run will end next spring. In some ways, his legacy is already written.

Pricing 77

Pricing Competition San Diego Patents 77

Both Sides of the Table

JUNE 3, 2010

Discussion: Had a long chat about PicClick , a company founded by Ryan Sit in San Diego. I don’t do advertising on my blog, but I thought it was worth mentioning Ryan in particular because he has an alternate model for doing a startup. Competition: Pingg, MyPunchbowl, TinyPrints , PaperlessPost. Hello, Chair.

Venture Capital 214

Venture Capital Startup Design S3 214

Xconomy

SEPTEMBER 19, 2016

A number of industry pundits addressed the crisis in blog posts that condemned “irresponsible price gouging” and described possible remedies, including transparent pricing, increased competition through accelerated approval of generics and value-based pricing of proprietary drugs. CEOs operate within the market landscape.

Pricing 40

Pricing Competition Blogging Journal 40

Xconomy

JANUARY 10, 2019

The market caps of some of the most successful tech titans reach as high as $1 trillion. Yet in 2018, perceptions about these dominant companies often reflected uneasiness and doubt—and for some, so did their stock performance. Some of these platform companies, taken together, now have a shared nickname: “FAANG,” which.

Platform 43

Platform Marketing Company Companies 43

Xconomy

JULY 29, 2016

But the company said this week that sales of Sovaldi and Harvoni, which share a common ingredient, sofosbuvir, have slowed with fewer patients starting on the drugs and prices undercut by fierce competition from AbbVie and Merck. The changing dynamic of the hepatitis C market will be acknowledged in the presidential campaign: yes or no.

Startup 40

Startup Study News Report 40

Xconomy

OCTOBER 21, 2016

—The hepatitis C drug telaprevir (Incivek) from Vertex Pharmaceuticals (NASDAQ: VRTX ) was once the fastest drug launch in history before competition wiped it off the map in three years. Wait til you get a load of this week’s roundup. TOP STORIES.

Research 40

Research San Diego Report Slides 40

Xconomy

AUGUST 10, 2018

First is Alnylam Pharmaceuticals, which has spent 16 years and over $2 billion to try to bring an unproven form of medicine, RNA interference (RNAi), to market. Two imminent FDA rulings on two separate drugs aren’t just noteworthy for the patients they’ll help, but the long and winding road their developers have taken to get to this point.

News 57

News Pricing Help Marketing 57

Xconomy

SEPTEMBER 7, 2016

It’s an interesting tactic that seems unusual in a competitive business environment, but makes sense when considering the constantly expanding sea of cyber threats—and solutions—through which organizations must wade. Cyber industry alliances, the thinking goes, could make customers’ cyber defenses stronger and easier to manage.

Press 40

Press Symantec Organization IBM 40

Xconomy

OCTOBER 18, 2016

But the drugs aren’t cures, and competition looms. In August 2014—just six months after moving into its new glass towers —Vertex announced plans to take telaprevir off the market. In its early days, Vertex helped bring two HIV drugs to market. Has Vertex has learned from its past missteps? Yet it wasn’t a fatal blow.

Startup 40

Startup Research Sales Organization 40

Xconomy

AUGUST 26, 2016

Critics say Mylan has been emboldened by the recall of EpiPen’s only competition last fall. Two days later, it paid AstraZeneca $550 million upfront for the rights to a group of antibiotics either already on the market or in late-stage testing. —Pfizer wasn’t done after scooping up Medivation.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

OCTOBER 28, 2016

The drug system went off the market in 2015, leaving Mylan’s EpiPen without competition and setting the stage for the furor over Mylan’s price hikes. . —Richmond, VA-based Kaleo Pharmaceuticals said it would bring its anti-allergy auto-injector Auvi-Q back next year.

Pricing 40

Pricing Conference News Study 40

Both Sides of the Table

JANUARY 31, 2010

TechCrunch ran my article yesterday as a guest post but I wanted to have a copy here for anybody who missed it and for future readers of this blog. a few days before the wheels came off of the market). We were immediately thrust into a globally competitive market for B2B collaboration tools. My family went without me.

Entrepreneur 308

Entrepreneur Startup Venture Capital Conference 308